Autor: |
Paolo Boscolo-Rizzo, Andrea D’Alessandro, Jerry Polesel, Daniele Borsetto, Margherita Tofanelli, Alberto Deganello, Michele Tomasoni, Piero Nicolai, Paolo Bossi, Giacomo Spinato, Anna Menegaldo, Andrea Ciorba, Stefano Pelucchi, Chiara Bianchini, Diego Cazzador, Giulia Ramaciotti, Valentina Lupato, Vittorio Giacomarra, Gabriele Molteni, Daniele Marchioni, Cristoforo Fabbris, Antonio Occhini, Giulia Bertino, Jonathan Fussey, Giancarlo Tirelli |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022) |
Druh dokumentu: |
article |
ISSN: |
1471-2407 |
DOI: |
10.1186/s12885-022-09327-4 |
Popis: |
Abstract Background Inflammatory blood markers have been associated with oncological outcomes in several cancers, but evidence for head and neck squamous cell carcinoma (HNSCC) is scanty. Therefore, this study aims at investigating the association between five different inflammatory blood markers and several oncological outcomes. Methods This multi-centre retrospective analysis included 925 consecutive patients with primary HPV-negative HNSCC (median age: 68 years) diagnosed between April 2004 and June 2018, whose pre-treatment blood parameters were available. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), systemic inflammatory marker (SIM), and systemic immune-inflammation index (SII) were calculated; their associations with local, regional, and distant failure, disease-free survival (DFS), and overall survival (OS) was calculated. Results The median follow-up was 53 months. All five indexes were significantly associated with OS; the highest accuracy in predicting patients’ survival was found for SIM (10-year OS = 53.2% for SIM |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|